Navigation Links
CranioFix2 Titanium Clamp System

ProductsCranioFix2 Titanium Clamp System
Company AESCULAP
Item CranioFix2 Titanium Clamp System
Features Integrated Strain-Relief Mechanism
  • Integrated, patented strain-relief mechanism
  • Reproducible fixation with defined force

Instrument-Free Application

  • Pre-fabricated assemly is ready for use
  • No additional instruments or appliers necessary
  • No heating or contouring pen necessary

Osteoplastic Outcome

  • Smooth flat surface and low-profile
  • Pre-fabricated knot sinks into indentation
  • Knot is not palpable or visible

Material

  • Absorbable polyester implants [Poly (L-lactide-co-D, L-Lactide) 70:30]
  • Non-absorbable suture (B.Braun PremiCron, USP 2/0)
  • High biocompatibility

Cranitomy Gap Pins

  • Simplifies positioning and centering of implants in craniotomy gap

No Cleaning, Reprocessing or Sterilization of Additional Instrumentation

  • Product is delivered sterile
  • All components are disposable
Description CranioFix2 is the next generation CranioFix Titanium Clamp System, which is up to 40% faster than the original CranioFix and all flap fixation systems on the market.
Info AESCULAP
Customer Service: (800) 282-9000
Web site: http://www.aesculapusa.com/

Related medicine products :

1. Hydroview Insertion Forceps - Titanium
2. Titanium Bayonet Forceps
3. Titanium Foot Activated Forceps
4. Craniofix Titanium Clamp
5. Craniofix Titanium Burr Hole Clamp
6. Lorenz 1.0 mm Titanium System
7. Lorenz 2.0 mm Flexible Titanium
8. Lorenz 1.5 mm Titanium System
9. Lorenz 2.0 mm Low Profile Titanium
10. Lorenz 2.0 mm Mini-plate Titanium
11. Anteater Titanium Microdiscectomy System
Breaking Medicine Technology:GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4New Executive Leadership and CEO Announced for BiPar Sciences 2Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 12946 1Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 12946 2Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 12946 3Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 12946 4Research shows that invisible hand guides evolution of cooperative turn taking 9182 1Research shows that invisible hand guides evolution of cooperative turn taking 9182 2Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 4702 1Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 4702 2